PIK3C2A and dyspepsia: Importantly, adverse events associated with AP therapy were infrequent, with only 2.2% of patients reporting adverse effects, primarily consisting of constipation (0.5%), elevated creatine phosphokinase (CPK) levels > 5 times the upper limit of normal (ULN), myalgia, and dyspepsia [59].